BCD-148 (eculizumab biosimilar) / Biocad - LARVOL DELTA

An Extension Clinical Study of BCD-148 for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated in Clinical Study No. BCD-148-2/NOCTURN (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Biocad

New P3 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - P3; N=28; Completed; Sponsor: Biocad; Active, not recruiting ➔ Completed

Clinical • Trial completion • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - P3; N=28; Active, not recruiting; Sponsor: Biocad; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® (clinicaltrials.gov) - P1; N=78; Completed; Sponsor: Biocad; N=39 ➔ 78

Clinical • Enrollment change

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - P3; N=28; Recruiting; Sponsor: Biocad

Clinical • New P3 trial